Search Results
Your search for ,ALl matches 18394 pages
Showing 1051 - 1100inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma
The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...
Benefit of Regular Physical Activity Prior to Cancer Diagnosis
Regular physical activity prior to a cancer diagnosis may be linked to a lower risk of disease progression and mortality, according to a recent study conducted by Professor Jon S. Patricios, MBBCh, of the University of Witwatersrand, Johannesburg, South Africa, and colleagues and published in the...
Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma
Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...
Monica M. Bertagnolli, MD, FACS, FASCO, Joins Friends of Cancer Research Board of Directors
Friends of Cancer Research (Friends) is honored to announce the addition of former Director of the National Institutes of Health (NIH) Monica M. Bertagnolli, MD, FACS, FASCO, to its Board of Directors. “Dr. Bertagnolli has built her incredible career around improving the lives of patients through...
Recent FDA Approvals in Lymphoma and in Rarer Tumors
The U.S. Food and Drug Administration (FDA) has approved brentuximab vedotin (Adcetris) in combination with lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma (LBCL)—including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising ...
Advancing Clinical Decisions With Circulting Tumor DNA: Insights From Recent Clinical Trials
Circulating tumor DNA (ctDNA) has evolved from an experimental biomarker to an increasingly actionable tool, informing treatment decisions throughout colorectal cancer care. Whether guiding adjuvant therapy intensification or de-escalation, refining organ-preservation strategies in rectal cancer,...
Exploratory Post Hoc Analysis of DUO-E Reveals Olaparib’s Benefit in Endometrial Cancer Subsets
The phase III DUO-E study evaluated the addition of the monoclonal antibody durvalumab to chemotherapy, and the benefit of maintenance durvalumab, with and without the PARP inhibitor olaparib, in advanced endometrial cancer. As reported this past year,1 the inclusion of durvalumab reduced the risk...
Misconceptions Regarding Skin Cancer Risk in the United States
Investigators may have uncovered associations between the reported number of sunburns and sociodemographic characteristics as well as the prevalence of protective skin behaviors adopted by U.S. adults, according to a recent study published by Etzel et al in the American Journal of Lifestyle...
AI Tool May Help to Predict Which Patients With Prostate Cancer May Benefit From Focal Therapy
A novel artificial intelligence (AI) tool, called Unfold AI, may help to determine which men with prostate cancer are most likely to benefit from partial gland cryoablation, according to a recent study published by Brisbane et al in BJUI Compass. The findings may play a key role in improving...
Checking PSA Levels Too Soon After Prostatectomy May Lead to Overtreatment, Says Study
In a paper published in JAMA Oncology, Tilki et al reported that the current standard monitoring of prostate-specific antigen (PSA) following radical prostatectomy—1.5 to 2 months—is too short to accurately identify recurrence and inform treatment decisions. Rather, PSA levels should be measured...
Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?
With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...
Race-Associated Molecular Differences and Treatment Response in Pancreatic Cancer
Investigators studied race-associated molecular differences in the pancreatic tumors of Black and White patients to determine whether such differences were associated with response to immunotherapy. The findings were published recently by Mandal et al in Cancer Research Communications and reinforce ...
Case 2: Next Steps After First-Line Induction Therapy for HR-Positive/HER2-Positive Metastatic Breast Cancer
This is Part 2 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss how to manage a...
In Case You Missed It: Abstracts on Novel Therapies in Gastrointestinal Cancers
The 2025 ASCO Gastrointestinal Cancers Symposium once again delivered a slate of high-impact studies spanning esophageal, gastric, hepatocellular, pancreatic, biliary tract, and colorectal malignancies. Experts in the field offered fresh perspectives on evolving standards of care, and investigators ...
The Real Cost Campaign May Have Prevented Thousands of Youths From Initiating E-Cigarette Use
The U.S. Food and Drug Administration’s (FDA) youth e-cigarette prevention campaign, known as The Real Cost, may have successfully reduced e-cigarette use among youth, according to a recent study published by MacMonegle et al in the American Journal of Preventive Medicine. Background The Real Cost...
Do Congenital Heart Defects Affect Cancer Risk in Newborns and Their Mothers?
Newborns with congenital heart defects may have a higher risk of developing childhood cancer compared to children born without a heart abnormality. Further, congenital heart defects in newborns may also signal an elevated cancer risk for their mothers. These findings were published recently by Huh...
MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC
The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...
Atezolizumab Plus Carboplatin/Paclitaxel in Advanced Thymic Carcinoma
In a Japanese phase II trial (MARBLE) reported in The Lancet Oncology, Shukuya et al found that atezolizumab plus carboplatin/paclitaxel showed promising results in patients with recurrent or metastatic thymic carcinoma. Study Details In the multicenter trial, 48 patients enrolled between June 2022 ...
Pembrolizumab and Bevacizumab in Untreated Melanoma Brain Metastases
In a phase II trial reported in Journal of Clinical Oncology, Weiss et al found that the combination of pembrolizumab and bevacizumab was active in patients with previously untreated melanoma brain metastases. Study Details In the trial, 37 patients, enrolled at Yale Cancer Center and Moffitt...
Stem Cell Transplant May Not Be Necessary in First Remission for Patients With Mantle Cell Lymphoma and Undetectable MRD
Autologous stem cell transplantation (ASCT) does not improve survival outcomes for patients with mantle cell lymphoma who achieve a deep first complete remission with undetectable measurable residual disease (MRD) after induction therapy, according to data presented during the 2024 American Society ...
Genomic Study Reveals Similarities, Differences in Ovarian Cancer Mutations Among Black, White Patients
Investigators may have uncovered nearly identical mutations to previously examined patient populations and several notable differences that may be clinically relevant among Black patients with ovarian cancer, according to a recent study published by Lawson-Michod et al in Cancer Research....
Enfortumab Vedotin Plus Pembrolizumab Continues to Show Benefit in Metastatic Urothelial Carcinoma
In previously untreated patients with locally advanced or metastatic urothelial carcinoma, use of the antibody-drug conjugate enfortumab vedotin-ejfv in combination with the PD-1 inhibitor pembrolizumab continues to demonstrate a significant survival benefit over chemotherapy, according to updated...
Cervical Precancer Incidence Decreases as HPV Vaccination Rates Rise
Recent findings from the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT), which were published by Gargano et al in the Morbidity and Mortality Weekly Report, revealed decreased incidences of cervical intraepithelial neoplasia (CIN)2+ and CIN3+ lesions among young women....
Study Finds No Clear Evidence That Red Wine Mitigates Cancer Risk
The consumption of alcohol has been associated with increased cancer risk, but red wine has been perceived by some as a healthier choice compared to white wine and other types of alcohol. Investigators evaluated whether the anticancer properties of red wine were greater in a recent study published...
Association of Pathogenic Variants With Cancer Mortality
In a study reported in the Journal of Clinical Oncology, Veenstra et al found that pathogenic variants (PVs) in ATM, CHEK2, or PALB2 were not associated with significant differences in mortality from breast, colorectal, or pancreatic cancer compared with the absence of such PVs. Study Details The...
Moderate-to-Vigorous Physical Activity May Lower Risk of Cardiovascular Disease–Related Mortality in Women With a Cancer History
Taking more daily steps and engaging in moderate-to-vigorous physical activity may both be associated with a reduced risk of cardiovascular disease–related mortality among postmenopausal women with a history of cancer, according to preliminary findings presented by Hyde et al at the American Heart...
Study Finds Wildfires Pose Health Threat for Patients Recovering From Lung Cancer Surgery
Studies have shown that not only does exposure to wildfire smoke, which contains fine particulate matter, increase the risk of developing lung cancer, it can also significantly reduce survival rates among patients recovering from lung cancer surgery. A large national study by researchers at the...
Two Initiatives Could Help Increase Oncogene Testing in Primary Care Settings
Investigators may have identified new strategies for use in the primary care setting to improve the detection of cancer-susceptibility genes, according to a recent study published by Swisher et al in JAMA Network Open. Background Up to 10% of cancers—including breast cancer, ovarian cancer,...
Addition of ADT to SBRT in Hormone-Sensitive Oligorecurrent Prostate Cancer
In an Italian single-center phase II trial (RADIOSA) reported in The Lancet Oncology, Marvaso et al found that the addition of androgen-deprivation therapy (ADT) to stereotactic body radiotherapy (SBRT) improved progression-free survival in patients with hormone-sensitive oligorecurrent prostate...
Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop
Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...
Cancer Incidence and Mortality in Southeast Asia for 2022
In a study reported in The Lancet Oncology, Dee et al identified cancer incidence and mortality rates for 2022 in the countries of southeast Asia. Study Details The study involved data from the GLOBOCAN 2022 database developed by the International Agency for Research on Cancer for the 11 countries...
Discussing Breast Density With Patients Following the FDA Mammography Quality Standards Act Mandate
In JAMA, Lee et al provided a concise, evidence-based summary to help clinicians discuss information regarding breast density and implement shared decision-making with patients following the U.S. Food and Drug Administration (FDA) Mammography Quality Standards Act mandate. Since September 2024,...
Greater Plant-Based Oil, Lower Butter Intake Could Improve Risk of Cancer-Related Mortality
Investigators have found that the consumption of plant-based oils instead of butter may provide beneficial health effects and potentially reduce the risk of premature mortality, according to recent findings presented at the American Heart Association Epidemiology, Prevention, Lifestyle &...
Breast Cancer Mortality Rates May Have Stopped Declining
Breast cancer mortality rates may have stopped declining in women older than 74 years and younger than 40 years, according to a recent study published by Monticciolo and Hendrick in the Journal of Breast Imaging. Background Breast cancer is the second leading cause of cancer-related mortality among ...
How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World
Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...
Partial-Gland Removal May Be an Option for Many Men With Prostate Cancer
A 5-year study on men that had primary partial-gland cryoablation shows that the procedure averted cancer recurrence in most patients while preserving urinary and sexual function. Led by researchers at New York University Grossman School of Medicine, the study tracked the patient outcomes after...
Genetic Factors Could Illuminate Which Patients With Prostate Cancer Could Benefit From Combination of Ipatasertib Abiraterone
Researchers have uncovered several biomarkers that may predict how patients with metastatic castration-resistant prostate cancer will respond to the novel combination of ipatasertib and abiraterone, according to a recent study published by Bono et al in European Urology. Background Prostate cancer...
MRD-Based Endpoint to Support Accelerated Approval of Treatment for Multiple Myeloma
In a pooled analysis reported in the Journal of Clinical Oncology, Shi et al found that a clinical trial endpoint of complete response with minimal residual disease (also known as measurable residual disease) at the 10-5 threshold (MRD-CR) at 9 or 12 months could be used to support accelerated...
Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC
In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...
MSTFCRC Updates Recommendations for Colonoscopy Preparation
Updated consensus recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer (MSTFCRC) address optimizing the quality of bowel preparation for colonoscopy. The document, published today by Jacobson et al, presents clinical strategies to improve bowel preparation as they apply...
Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC
Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...
Francis S. Collins, MD, PhD, Retires From the National Institutes of Health
Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...
Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...
The Importance of Diversity in Clinical Research
The Cancer Drug Development Forum (CDDF) held its annual conference in the Netherlands from February 3–5, 2025. Under the title “Challenges, Advances, and Open Questions in Global Cancer Drug Development and Clinical Trials,” the workshop focused on diversity and real-world evidence in anticancer...
7-Year Follow-up of ABC Trial: Ipilimumab/Nivolumab vs Nivolumab Alone in Melanoma Brain Metastases
As reported in The Lancet Oncology by Long et al, 7-year follow-up of the Australian phase II ABC trial showed continued benefit of ipilimumab/nivolumab vs nivolumab alone in patients with asymptomatic melanoma brain metastases. Study Details In the open-label multicenter study, 63...
Breast-Conserving Surgery Linked to Improved Sexual Well-Being Compared With Postmastectomy Breast Reconstruction
Breast-conserving therapy may be associated with improved sexual well-being compared with mastectomy followed by breast reconstruction in patients with breast cancer, according to a recent study published by Stern et al in Plastic and Reconstructive Surgery. Background Many patients with breast...
Overall Survival and HRQOL with Addition of [177Lu]Lu-PSMA-617 to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In an analysis of an Australian phase II trial (ENZA-p) reported in The Lancet Oncology, Emmett et al reported that the addition of lutetium-177–labeled PSMA-617 (LuPSMA) to enzalutamide improved overall survival and several aspects of health-related quality of life (HRQOL) in the first-line...
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early HER2-Positive Breast Cancer
In an analysis from the ShortHER trial reported in JAMA Oncology, Dieci et al identified 10-year outcomes with 9 weeks or 1 year of adjuvant trastuzumab plus chemotherapy according to level of tumor-infiltrating lymphocytes (TILs) in patients with early HER2-positive breast cancer. Study Details...
Top Picks From SABCS 2024
Among the high-quality abstract presentations at the 2024 San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCO Post asks our Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman...
Cabozantinib/Atezolizumab in Locally Advanced or Metastatic Urothelial Carcinoma
In a multicohort phase Ib study (COSMIC-021) reported in the Journal of Clinical Oncology, Sumanta K. Pal, MD, FASCO, and colleagues identified the activity of cabozantinib plus atezolizumab in a cohort of patients with locally advanced or metastatic urothelial carcinoma according to first-line...
